Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Unexpected rosuvastatin-canagliflozin adverse effect reported

Key clinical point: A case report cited a patient who developed acute rhabdomyolysis linked with rosuvastatin toxicity within days of starting canagliflozin treatment.

Major finding: The patient showed a plasma rosuvastatin level of 176 ng/mL, more than 15-fold above the mean expected level.

Study details: Case report from a Toronto-area hospital.

Disclosures: The study received no commercial funding. Dr. Juurlink and coauthors had no disclosures.


Brailovski E et al. Ann Intern Med. 2020 Aug 3. doi: 10.7326/L20-0549.